Isthmus Partners LLC Buys 8,667 Shares of DexCom, Inc. $DXCM

Isthmus Partners LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 5.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 176,453 shares of the medical device company’s stock after buying an additional 8,667 shares during the period. Isthmus Partners LLC’s holdings in DexCom were worth $11,711,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Phoenix Financial Ltd. bought a new stake in shares of DexCom in the 4th quarter valued at about $256,000. Simmons Bank grew its position in shares of DexCom by 9.9% in the 4th quarter. Simmons Bank now owns 3,545 shares of the medical device company’s stock valued at $235,000 after buying an additional 320 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. grew its position in shares of DexCom by 327.2% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 1,192 shares of the medical device company’s stock valued at $86,000 after buying an additional 913 shares during the last quarter. Western Wealth Management LLC bought a new stake in shares of DexCom in the 4th quarter valued at about $235,000. Finally, Allworth Financial LP grew its position in shares of DexCom by 13.9% in the 4th quarter. Allworth Financial LP now owns 5,622 shares of the medical device company’s stock valued at $373,000 after buying an additional 686 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: DexCom outlined a 2030 growth plan calling for at least 10% annual revenue growth through 2030, along with margin targets that suggest improving profitability over time. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: The company authorized a new $1 billion share buyback, which can support the stock by signaling confidence in future cash flow and returning capital to shareholders. Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
• Positive Sentiment: Management also highlighted next-generation products, including the G8 glucose sensor and dual-analyte sensing, which could expand DexCom’s competitive position and addressable market. Dexcom to add 2 board directors with activist investor Elliott
• Positive Sentiment: DexCom and Elliott Investment Management agreed to add two independent directors to the board and revise governance, a move that may improve oversight and strategic execution. Dexcom to appoint two directors, revamp board committee with Elliott
• Neutral Sentiment: Wall Street sentiment remains constructive overall, with a “Moderate Buy” consensus and an average price target above recent trading levels, though there are still some hold and underweight ratings in the mix. Are Wall Street analysts bullish on DexCom’s stock?
• Negative Sentiment: Director Bridgette Heller sold 1,012 shares, but the transaction was small and was made under a pre-arranged trading plan, so it is less likely to be a major negative signal. Bridgette Heller Sells 1,012 Shares of DexCom (NASDAQ:DXCM) Stock

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of analyst reports. Benchmark initiated coverage on DexCom in a research report on Monday. They issued a “buy” rating and a $77.00 price target on the stock. Sanford C. Bernstein set a $77.00 price target on DexCom in a research report on Friday, May 1st. Mizuho set a $75.00 price target on DexCom in a research report on Friday, May 1st. Evercore upgraded DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target on the stock in a research report on Tuesday, March 24th. Finally, Weiss Ratings upgraded DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, March 4th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and an average target price of $83.22.

Insiders Place Their Bets

In related news, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total transaction of $107,168.00. Following the sale, the executive vice president directly owned 111,204 shares in the company, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the sale, the director owned 25,007 shares in the company, valued at $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,412 shares of company stock worth $278,143 over the last quarter. 0.28% of the stock is currently owned by corporate insiders.

DexCom Stock Up 6.6%

DXCM stock opened at $61.63 on Friday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. The stock’s 50 day moving average is $63.46 and its 200-day moving average is $65.89. The firm has a market capitalization of $23.78 billion, a PE ratio of 26.34, a P/E/G ratio of 1.00 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same period last year, the company posted $0.32 earnings per share. Sell-side analysts expect that DexCom, Inc. will post 2.56 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.